We have previously shown that co-transplantation of islets and Mesenchymal Stem Cells (MSCs) improves islet graft function and revascularisation, which was associated with the maintenance of normal islet morphology. The aim of the current study was to determine whether maintaining islet morphology in the absence of additional islet-helper cells would improve transplantation outcome in diabetic mice. Islets were isolated from C57BL/6 mice. Recipient streptozotocin-diabetic C57BL/6 mice were transplanted with a minimal mass of 150 islets as a single pellet or islets that were either manually dispersed or dispersed within a matrigel plug beneath the kidney capsule. Blood glucose concentrations were monitored for one month. Islet graft morphology and vascularisation were analysed by histology. Islets dispersed either alone or within matrigel plugs maintained near normal morphology, in contrast to pelleted islets, where individual islets fused to form large endocrine aggregates. The vascularisation of manually dispersed islets and islets dispersed within matrigel plugs was increased relative to respective control pelleted islet grafts. After one month 1/6 mice transplanted with pelleted islets cured compared to 5/6 mice transplanted with manually dispersed islets. The curative capacity of islets dispersed in matrigel was also better than that of pelleted islets (5/8 islet-matrigel implanted mice vs. 1/7 mice transplanted with pelleted islets cured by one month). Therefore, this study demonstrates that the maintenance of islet morphology is associated with improved graft function and revascularisation in diabetic mice.
Citation: Rackham CL, Jones PM, King AJF (2013) Maintenance of Islet Morphology Is Beneficial for Transplantation Outcome in Diabetic Mice. PLoS ONE 8(2): e57844. doi:10.1371/journal.pone.0057844
Editor: Miguel López, University of Santiago de Compostela School of Medicine – CIMUS, Spain
Received: November 23, 2012; Accepted: January 27, 2013; Published: February 25, 2013
Copyright: © 2013 Rackham et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Biotechnology and Biological Sciences Research Council (CR), Novo Nordisk UK Research Foundation (A. K) and Diabetes UK (AK, PJ; 06/0003387; 11/0004290) for funding this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Allogeneic islet transplantation represents a viable therapy for the treatment of type 1 diabetes (T1D) in a selected group of patients. Remarkable improvements in the clinical islet transplantation field have been made with the development of the Edmonton protocol  and subsequent improvements on the original protocol . However, the extensive loss of islets during the post-transplantation period means that individual graft recipients require multiple donors, further limiting the clinical applicability of islet transplantation as a therapy for T1D. Experimental studies in animal models are therefore being directed towards understanding the reasons for post-transplantation islet failure and to developing strategies to enhance the survival, function and engraftment of transplanted islets.
Delivering islets via the clinically-relevant intraportal route is technically challenging in experimental studies using rodents and it complicates subsequent graft retrieval for post-transplantation analysis, so extrahepatic sites are often used. In addition, while infusing islets into the hepatic portal vein is relatively simple and non-invasive in humans, experimental evidence is emerging that this site places the grafts into a hostile microenvironment which may be responsible, at least in part, for the post-transplantation loss of islet function , so the use of alternative sites may have clinical benefits. However, transplantation of islets as pellets at extrahepatic sites results in the fusion of individual islets and formation of large endocrine aggregates –, which may be deleterious to their function. In a recent study in which we co-transplanted mesenchymal stem cells (MSCs) with islets beneath the kidney capsule in diabetic mice, we noted profound alterations in graft morphology when compared to islet alone grafts, with the MSCs maintaining normal islet size and architecture at the subcapsular site . This was associated with increased vascularisation of the transplanted islets and beneficial outcomes for graft function and glycemic control when compared to islet-alone grafts. MSCs may influence graft function through multiple mechanisms –, so in the current study we have investigated whether maintenance of islet morphology per se influences islet transplantation outcomes, in the absence of MSCs or any alternative supportive cell type. Specifically, we have used two different non-cell based experimental strategies to maintain islet morphology in the renal subcapsular site and assessed the effects on islet function in vivo compared to conventional implantation of islet pellets.
Materials and Methods
All animal procedures were approved by our institution's Ethics Committee and carried out under license, in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 (Project licence: PPL no. 70/6770). All animals had free access to water and pelleted food throughout experiments. For all surgical procedures mice were anesthetised with isofluorane. Buprenorphine was administered at a dose of 30 µg/kg, as an analgesic and all efforts were made to minimise suffering.
Male C567Bl/6 mice (Charles River, Margate, UK) aged 8–12 weeks were used as donors and recipients. Mice were made diabetic by i.p. streptozotocin (STZ) injection (180 mg/kg; Sigma-Aldrich, Poole, UK) and those with a non-fasting blood glucose concentration of ≥20 mmol/l were used as recipients. Blood glucose concentrations were determined using a blood glucose meter and strips (Accu-Chek; Roche, Burgess Hill, UK).
Islets were isolated by collagenase digestion (1 mg/ml; type XI; Sigma-Aldrich) followed by density gradient separation (Histopaque-1077; Sigma-Aldrich). After washing with RPMI-1640, islets were picked into groups of 150 for transplantation, as described previously .
Transplantation of pelleted and manually dispersed islets
The first experimental series was designed to determine whether manually spreading islets out beneath the kidney capsule was able to maintain normal islet size and morphology. Mice were transplanted with 150 freshly isolated islets either as a single cluster of islet cells that had been centrifuged into pellets (pelleted islets transplant group) in PE50 polyethylene tubing (Becton Dickinson, Sparks, MD, USA) before placing underneath the kidney capsule using a Hamilton syringe (Fisher, Pittsburg, PA, USA). Alternatively, islets were suspended in media and aspirated into PE50 polyethylene tubing and sedimented by gravity. Islets were then spread out over the majority of the upper surface of the kidney capsule, using the Hamilton syringe (manually dispersed islet transplant group).
Transplantation of islets dispersed in matrigel plugs
The second series of experiments used an alternative approach to maintain normal islet size and morphology, which was to disperse the islets in matrigel plugs beneath the kidney capsule. Matrigel (Becton Dickinson marathon growth factor reduced, high concentration) was kept at −20°C until use. 250 µl aliquots were defrosted at 4°C overnight before transplantation. Each aliquot was made up to 350 µl using PBS and 1 U heparin, before adding 150 freshly isolated islets whilst being careful to avoid any bubble formation. Matrigel has a liquid gelatinous state at 4°C, but solidifies at 37°C. Therefore, islet-matrigel preparations were kept on ice until immediately before transplantation. The matrigel solution was used to fill dead space in the Hamilton syringe and PE50 polyethylene tubing. 150 islets in the matrigel solution were aspirated into the tubing and then implanted beneath the kidney capsule, ensuring that the islet-matrigel solution was spread over the majority of the upper surface of the kidney.
The body weight and blood glucose concentrations of recipient mice were monitored every 3–4 days for a 1 month monitoring period. Cure was defined as non-fasting blood glucose concentrations ≤11.1 mmol/l for at least two consecutive readings, without reverting to hyperglycaemia on any subsequent day. At 1 month in some cured animals the graft-bearing kidney was removed to determine whether graft removal would result in reversion to hyperglycaemia. Mice were killed 3–4 days later and the graft-bearing kidney removed for histological analysis.
Graft bearing kidneys and pancreata were fixed in 4% (vol./vol.) formalin and paraffin-embedded. Sections (5 µm thick) were stained for insulin, glucagon and microvascular endothelial cells (ECs). For CD34 staining (detection of ECs), antigen retrieval was required (2 min in 10 mmol/l citric acid solution pH 6.0 in a pressurised cooker). Sections were incubated for 1 h at room temperature in either polyclonal guinea pig anti-insulin antibody (1∶1000; Dako, Ely, UK) for the detection of β-cells, or with a monoclonal rat anti-CD34 antibody (1∶500 AbD serotec, Kidlington, UK) for the detection of ECs. Slides were then incubated for 1 h at room temperature with either a goat biotin anti-guinea pig antibody (1∶200; Jackson Immunolaboratories, West Grove, PA, USA) or a rabbit biotinylated anti-rat antibody (1∶200; Vector Laboratories, Peterborough, UK). Sections were counterstained with hematoxylin. For immunofluorescence labeling of insulin, a polyclonal guinea pig anti-insulin antibody (1∶100; Jackson) was used (1 h at room temperature) with a Texas Red anti-guinea pig secondary antibody (1∶40; Jackson; 1 h at room temperature). For immunofluorescence labeling of glucagon, a monoclonal mouse anti-glucagon antibody (1∶200; Sigma-Aldrich, Dorset, UK) was used (1 h at room temperature) with a FITC anti-mouse secondary antibody (1∶40; Jackson; 1 h at room temperature).
Evaluation of graft morphology and vascular density
For each animal ≥5 tissue sections from different regions of the graft were analysed for vascular density. Graft morphology was evaluated by measuring the total endocrine area per graft section and extent of islet fusion as previously described . Briefly, to evaluate the extent of fusion between individual islets, the area of individual endocrine aggregates was measured. An individual endocrine aggregate was defined as an area of insulin-positive tissue separated from any other adjacent insulin positive tissue by ≥50 µm of non-endocrine tissue (insulin-negative). The area of islets in the pancreas of healthy non-diabetic control C57Bl/6 mice was measured as a control. Area was determined using image J software (http://rsbweb.nih.gov/ij/) and the vascular density (number of CD34-positive ECs per square millimeter of endocrine tissue) was determined.
Statistical analysis used Student's t test or ANOVA, as appropriate. Two-way repeated measurement ANOVA was used with Bonferroni's post hoc test to analyze repeated measurements in the same animal at different time points. A Kaplan–Meier survival curve was used to identify differences in the time to cure between groups. A p value of p<0.05 was considered significant. All data are expressed as means ± SEM.
Morphology and vascularisation of pelleted and dispersed islet grafts
At 1 month post transplantation graft-bearing kidneys were harvested and visualised under a dissecting microscope. In the grafts of mice transplanted with pelleted islets, individual islets could not be distinguished from each other within the single mass of compacted islets. Whereas, individual islets were clearly discernible in the dispersed islet grafts and occupied a larger area beneath the kidney capsule compared to pelleted islets. Figure 1 shows the morphology of graft material retrieved at 1 month post transplantation, demonstrating that the technical procedure of manually spreading islets beneath the kidney capsule was able to maintain the typical size and morphology of endogenous pancreatic islets, in comparison with the amorphous mass of endocrine tissue formed in the control pelleted islets transplant group. Insulin immunostaining of graft sections from mice transplanted with pelleted islets revealed a single amorphous mass of aggregated insulin-positive endocrine tissue in the majority of sections analysed (Figure 1a), resulting from the fusion of individual islets beneath the kidney capsule. In contrast, for most of the graft sections from dispersed islet transplant recipients, there was little evidence of any fusion between individual islets, with the spherical morphology of individual islets still clearly discernible (Figure 1b). Immunostaining for glucagon-positive alpha cells indicated that the core-mantle segregation of islet endocrine cells was disrupted in pelleted islet grafts (Figure 1c), whereas alpha cells were located at the periphery of individual islets in dispersed islet grafts (Figure 1d). The total endocrine area (immunostained with insulin) per graft section was reduced in dispersed islet grafts (Figure 1e), demonstrating that the isolated islets had been dispersed over a larger area beneath the kidney capsule compared to that of pelleted islet controls. The extent of islet fusion was quantified to determine the extent to which manually spreading islets at the implantation site can prevent the formation of large aggregated endocrine masses. Islet area was also quantified in endogenous pancreatic islets from healthy age-matched non-diabetic control C57Bl/6 mice as a reference to help describe the extent to which islet fusion had occurred/been prevented within grafts. The mean area of islets in the pancreas of non-diabetic mice was 19,422±1,861 µm2, n≥20 islets in each pancreas from 4 mice. The average area of each single endocrine aggregate per graft section in the dispersed islet grafts was approximately 25% of that seen for pelleted islet grafts (Figure 1f).
A, B Representative sections of pelleted islet (a) and manually dispersed islet grafts (b) at one month post transplantation beneath the kidney capsule, immunostained with insulin antibodies. A. Pelleted islet graft, where islets have typically aggregated to form a single amorphous endocrine mass in which the spherical morphology of individual islets can no longer be discerned. B. Dispersed islet graft, where large endocrine aggregates formed by the fusion of multiple islets are not present, but where multiple individual islets can still be seen in individual graft sections, original magnification ×100, scale bars are 100 µm. C, D Representative sections of pelleted islet (c) and manually dispersed islet grafts (d) at one month post transplantation, dual stained with insulin (red) and glucagon (green) antibodies, original magnification ×200, scale bars are 25 µm. E. Total endocrine area in graft sections; n = 4 animals per transplant group, *p<0.05, Student's t test. F. Average individual endocrine aggregate area in graft sections; n = 4 animals per transplant group, *p<0.05 vs. pelleted islet grafts, Student's t test.
CD34 antibodies were used to immunostain microvascular ECs in 1 month grafts consisting of pelleted and dispersed islets. The endocrine tissue of pelleted islet grafts contained large areas devoid of ECs (Figure 2a), whereas ECs were located throughout the individual islets clearly visible in dispersed islet grafts (Figure 2b). The endocrine vascular density was significantly higher in the dispersed islet grafts, compared to pelleted islet grafts (Figure 2c).
Immunostaining of microvascular endothelial cells (ECs) with CD34 antibodies in pelleted (a) and dispersed (b) islet grafts. Original magnification ×400, scale bars 25 µm. C. Vascular density of endocrine components in 1 month grafts consisting of pelleted (black bar) or dispersed (white bar) islets. *p<0.05 vs. pelleted islet grafts, n = 4 animals per group, Student's t test.
Efficacy of pelleted and dispersed islet transplants in vivo
Dispersion of the islet transplant underneath the kidney capsule produced superior transplantation outcomes compared to that of islets transplanted as a single pellet/cluster of islets, as shown in Fig. 3. The average blood glucose concentrations of mice with dispersed islet transplants was significantly lower than that of mice transplanted with pelleted islets at 21 and 28 days post transplantation (Figure 3a). After one month, only 1/6 mice transplanted with pelleted islets had cured, compared to 5/6 mice with dispersed islet transplants (Figure 3b). The average time to reverse hyperglycaemia for mice with dispersed transplants was 24±2 days, with only one mouse in the pelleted islets transplant group curing at all, at 28 days post transplantation. All nephrectomised mice reverted to severe hyperglycaemia, with blood glucose concentrations of ≥33.7 mmol/l 3 days after removal of the graft-bearing kidney. In accordance, immunohistochemical analysis of the STZ-pancreata of graft recipients revealed no detectable signs of β-cell regeneration as determined by the very low levels of insulin immunoreactivity. In contrast, glucagon immunoreactivity was readily detectable in the STZ pancreata of graft recipients. One mouse in the dispersed islet transplant group was excluded from the study as histological analysis of the graft tissue clearly showed that the dispersion technique had not worked, as was evident from the large endocrine aggregates present.
A. Blood glucose concentrations of mice with pelleted (continuous line) or manually dispersed islet transplantation (dashed line), *p<0.05, Two-Way RM ANOVA with Bonferroni post hoc test, n = 6 for both transplant groups. B. Percentage of mice remaining diabetic (blood glucose concentration >11.1 mmol/l) after transplantation as in A, p = 0.02 Kaplan–Meier, n = 6 for both transplant groups.
Morphology and vascularisation of matrigel-implanted islets
At 1 month post transplantation graft-bearing kidneys were harvested and visualised under a dissecting microscope. The implanted islets were identifiable in both transplant groups, but their appearance was clearly different, as shown in Fig. 4. The grafts of mice transplanted with pelleted islets were present as a single mass of compacted islets (Figure 4a). The grafts of mice transplanted with islets in matrigel appeared as islets dispersed over a larger area beneath the kidney capsule (Figure 4b), with little evidence of single pellets/clusters of islets in any of the mice.
Photographs of islet-graft bearing kidneys at one month post transplantation. Islets transplanted as a single islet pellet/cluster (a) and islets spread beneath the kidney capsule in matrigel (b), at one month after transplantation. Photographs were taken with a digital camera (Panasonic Lumix DMC-ZX1) through a dissecting microscope. Arrow indicates aggregated islets.
Figure 5 demonstrates the typical graft morphology of pelleted islets and islets dispersed in matrigel at 1 month post transplantation, demonstrating that dispersing islets within matrigel is able to maintain islet size and morphology more closely to endogenous pancreatic islets than that seen in pelleted islet grafts. As shown in Figure 5, insulin immunostaining of pelleted islet grafts showed a single large amorphous endocrine mass in the majority of sections analysed (Figure 5a), whereas in the islet-matrigel transplants there was very little evidence of any fusion between individual islets with the spherical outline of individual islets still clearly discernible (Figure 5b). The endocrine cell distribution was disorganised in pelleted islets grafts, with glucagon-positive alpha cells distributed throughout the aggregated endocrine mass (Figure 5c), confirming our observations demonstrated in Figure 1. Similarly to dispersed islet grafts; the normal core-mantle segregation of alpha cells was maintained in matrigel-implanted islets (Figure 5d). Although the total endocrine area (immunostained with insulin) was comparable between mice transplanted with pelleted islets and those receiving matrigel-implanted islets (Figure 5e), the graft morphology was clearly different. Quantification of islet fusion showed that the average area of each individual endocrine aggregate in the graft sections of matrigel-implanted mice was ∼15% of that seen in pelleted islet grafts (Figure 5f), indicating that this represents a reliable method for preventing islet fusion.
Representative sections of pelleted islet grafts (a) and matrigel-implanted islets (b) at one month post transplantation beneath the kidney capsule, immunostained with insulin antibodies, original magnification ×100, scale bars are 100 µm. A. Pelleted islet graft representing the large endocrine aggregates formed from the fusion of individual islets. B. Matrigel-implanted islet graft where the rounded morphology of individual islets separated by large areas of non-endocrine tissue, can be clearly visualised. C, D Representative sections of pelleted islet (c) and matrigel-implanted islets (d) at one month post transplantation, dual stained with insulin (red) and glucagon (green) antibodies, original magnification ×200, scale bars are 25 µm. E. Total endocrine area in graft sections; n = 4 animals per transplant group, p>0.2, Student's t test. F. Average individual endocrine aggregate area in graft sections; n = 4 animals per transplant group, *p<0.05 vs. pelleted islet grafts, Student's t test.
Large areas of endocrine tissue were devoid of ECs in the grafts consisting of pelleted islets (Figure 6a), whereas ECs were distributed throughout the endocrine tissue in grafts consisting of matrigel-implanted islets (Figure 6b). The vascular density of the endocrine tissue in grafts consisting of matrigel-implanted islets was significantly elevated compared to control pelleted islet grafts (Figure 6c). There were no differences between the vascularisation of matrigel implanted islets and dispersed islets (973.30±36.83 and 1,143.89±135.98 ECs/mm2, p>0.2, n = 4), nor were there any differences in the average area of individual endocrine aggregates per graft section (22,144±3,777 and 23,639±4,352 µm2, p = 0.8, n = 4). However, the total endocrine area per graft section was significantly higher in matrigel-implanted islet grafts than dispersed islet grafts (97,458±16,348 and 35,564±7,898 µm2, n = 4, p<0.05), indicating that manual dispersion of islets ensured that individual islets were spread out over a larger area beneath the kidney capsule than matrigel-implanted islets that were less spread out due to the solid matrigel support.
CD34 immunostaining of microvascular endothelial cells (ECs) in pelleted islet grafts (a) and matrigel-implanted islet grafts (b) at 1 month post transplantation. Original magnification ×400, scale bars 25 µm. C. Vascular density of endocrine components in 1 month grafts consisting of pelleted (black bar) or matrigel-implanted (white bar) islets. *p<0.05 vs. pelleted islet grafts, n = 4 animals per group, Student's t test.
Efficacy of matrigel-implanted islets in vivo
Transplantation of islets in matrigel plugs produced superior transplantation outcomes to that of pelleted islets, as shown in Fig. 7. The average blood glucose concentrations of islet-matrigel implanted mice were significantly lower than in mice transplanted with pelleted islets at 14 days post transplantation (Figure 7a). The curative capacity of islets in matrigel was better than that of pelleted islets, with 5/8 islet-matrigel implanted mice curing by one month, compared to only 1/7 control mice transplanted with pelleted islets (Figure 7b). The average time to reverse hyperglycaemia for islet-matrigel implanted mice was 10±4 days, with one mouse in the pelleted islet transplant group curing after 21 days.
A. Blood glucose concentrations of mice transplanted with pelleted islets alone (continuous line) or islets dispersed in matrigel (dashed line), beneath the kidney capsule, *p<0.05, Two-Way RM ANOVA with Bonferroni post hoc test, n = 7-8. B. Percentage of mice remaining diabetic (blood glucose concentration >11.1 mmol/l) after transplantation as in A, p = 0.02 Kaplan–Meier, n = 7-8.
In the current study, we used a syngeneic minimal islet mass transplantation model in STZ-induced diabetic mice to demonstrate that maintaining normal islet size and morphology at the implantation site is beneficial for transplantation outcome. We used two different experimental approaches to maintain normal islet morphology by preventing islet fusion and thus limiting the formation of large amorphous endocrine aggregates. The first approach was to transplant islets at the renal subcapsular site by manually dispersing individual islets beneath the kidney capsule, as opposed to the standard procedure of transplanting them as a single pellet or cluster. In the second approach, islets were mixed with and transplanted in matrigel to ensure that the transplanted islets were physically separated beneath the kidney capsule by the solid matrigel support.
Our morphological measurements showed that manually dispersing islets beneath the renal capsule reduced the size of individual endocrine aggregates by approximately 75 percent compared to grafts of pelleted islets, consistent with maintaining normal endogenous pancreatic islet size at the subcapsular implantation site. Providing the transplanted islets with the physical support of a matrigel matrix was equally effective in maintaining individual islet morphology under the kidney capsule, producing similar effects on islet distribution and anatomy at the graft site. Immunostaining of islet α-cells for glucagon expression showed that islet architecture was maintained in both the dispersed and matrigel islet grafts, with the majority of graft sections showing a peripheral rim of α-cells surrounding the β-cell core, in contrast to the disorganised core-mantle cellular architecture in pelleted islet grafts . Both methods of maintaining islet structure were also associated with significantly enhanced revascularisation of the graft endocrine tissue, as demonstrated by increased vascular density when compared to conventional pelleted islet grafts.
Immunohistochemical analysis of the STZ pancreata at one month post transplantation revealed very low numbers of insulin-positive cells and all cured mice that were nephrectomised reverted to severe hyperglycaemia (blood glucose ≥33.7 mmol/l). This is consistent with our previous observations where we demonstrated that spontaneous pancreatic β-cell regeneration is unlikely to account for improved glycaemia in high dose STZ-diabetic mice over a 1 month monitoring period. Instead, the maintenance of islet anatomy in grafts consisting of both dispersed islets and matrigel-implanted islets is associated with improved transplantation outcome in the current study. Thus, when compared to conventional islet pellets, both methods to maintain islet morphology and size enhanced the rate and frequency of reversion to normoglycaemia in STZ-induced diabetic mice and showed significant improvements in overall glycemic control. Notably, we observed an initial decrease in blood glucose in all islet graft recipients, which we believe is not physiologically relevant. Instead, this is likely to be due to extensive islet cell death ,  and subsequent insulin leakage from dying cells during the immediate post transplantation period. The real differences in glycaemia are present at 2–4 weeks post transplantation when the anatomical remodelling and revascularisation process are known to be completed , .
Matrigel is a solubilised basement membrane preparation extracted from an Engelbreth-Holm-Swarm mouse sarcoma , in which the main components are ECM proteins such as laminin, collagen IV, fibronectin and perlecan . These basement membrane proteins are involved in interactions between intraislet ECs and endocrine cells ,  and a number of studies have suggested that loss of integrin signalling between islets and the surrounding ECM proteins is detrimental to islet function , , . Conversely, entrapment of islets within ECM scaffolds is reported to enhance islet function – and survival , , , . In the present study we did not detect any additional in vivo benefit of suspending the islets in matrigel over and above the improved function associated with the maintenance of islet morphology by physical dispersion below the renal capsule. This does not imply that islet-ECM interactions are unimportant, but suggests that interactions with the specific matrix components present in matrigel are neither beneficial nor detrimental for islet survival and function in vivo when transplanted to the renal subcapsular site. Thus, the beneficial effects of matrigel in our experimental model can be attributed to its role as a physical support to maintain islet anatomy.
There are a number of mechanisms through which maintained islet architecture may have beneficial effects on graft function and transplantation outcome in our studies. Hypoxia-related dysfunction  and cell death , , ,  is an important confounding factor in the survival of avascular islets during the immediate post-transplantation period. Oxygen tension gradients across fused islet tissue have been demonstrated previously , with higher partial pressures of oxygen at the periphery of the islet graft compared with centrally located parts of the graft. Diffusion of oxygen and nutrients will be more effective in smaller endocrine aggregates enhancing their survival and function until the re-establishment of the islet vasculature. Small islet aggregates have previously been shown to be superior to large intact islets as graft material in diabetic mice, with improved transplantation outcomes being associated with reduced hypoxia-related necrosis in the small islet aggregates . Importantly, this benefit of small islet aggregates over large intact islets was demonstrated using encapsulated islets which do not revascularise in vivo, so the improved islet function was independent of any influence on islet revascularisation.
Graft revascularisation is obviously important for subsequent function and inadequate revascularisation of transplanted islets at a number of implantation sites is associated with deleterious outcomes –, whereas improvements in graft revascularisation are associated with improved islet function and long-term survival –. Our results demonstrate that maintaining individual islets at the graft site resulted in a significant enhancement of revascularisation, consistent with a previous report of superior revascularisation of small, compared to larger islets . Similarly, in our previous study where we co-transplanted islets with MSCs, the resultant smaller endocrine aggregates had an enhanced vascular density compared to that of the large endocrine masses formed in mice implanted with islets alone .
Intra-islet interactions are known to be important for normal islet function ,  and disruption of islet architecture is associated with impaired secretory responses to a range of physiological stimuli. Maintaining anatomically correct islet architecture may therefore further enhance graft function by facilitating the numerous interactions between islet cells  that are required for normal insulin secretion , .
Our observations using the renal subcapsular graft site are in accordance with recent studies of intramuscular islet transplantation, in which islets grafted as clusters developed central fibrosis , whereas transplanting the islets in a ‘pearls-on-a-string’ configuration, such that they are engrafted essentially as single islets, was associated with improved transplantation outcomes . This suggests that the beneficial impact of maintaining islet anatomy during transplantation is not graft site-specific.
In conclusion, there is mounting evidence that the current intraportal route for clinical islet transplantation places the grafts into a hostile microenvironment and confers multiple and perhaps avoidable stresses upon the transplanted islets , so efforts are being made to identify alternative optimal implantation sites for islets. The current study suggests that preventing the fusion of islets at extrahepatic sites represents an important strategy for promoting islet engraftment, which may contribute to achieving routine single donor islet transplantation , , thereby increasing the availability of donor islet tissue and enabling the more widespread application of islet transplantation as a therapy for T1D.
Conceived and designed the experiments: CR PJ AK. Performed the experiments: CR AK. Analyzed the data: CR PJ AK.
- 1. Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth E, et al. (2000) Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen. N Engl J Med 343: 230–238.
- 2. Shapiro AM (2011) Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Tran 16: 627–631.
- 3. Carlsson PO (2011) Influence of microenvironment on engraftment of transplanted beta-cells. Ups J Med Sci 116: 1–7.
- 4. Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, et al. (1996) Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 45: 1161–1167.
- 5. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, et al. (2002) Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51: 66–72.
- 6. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, et al. (2011) Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 54: 1127–1135.
- 7. Figliuzzi M, Cornolti R, Perico N, Rota C, Morigi M, et al. (2009) Bone Marrow–Derived Mesenchymal Stem Cells Improve Islet Graft Function in Diabetic Rats. Transpl Proc 41: 1797–1800.
- 8. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, et al. (2009) Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 58: 1797–1806.
- 9. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, et al. (2009) Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J autoimmun 32: 116–124.
- 10. Longoni B, Szilagyi E, Quaranta P, Paoli GT, Tripodi S, et al. (2010) Mesenchymal Stem Cells Prevent Acute Rejection and Prolong Graft Function in Pancreatic Islet Transplantation. Diabetes Technol The 12: 435–446.
- 11. Ito T, Itakura S, Todorov I, Rawson J, Asari S, et al. (2010) Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation 89: 1438–1445.
- 12. Berman DM, Willman MA, Han D, Kleiner G, Kenyon NM, et al. (2010) Mesenchymal Stem Cells Enhance Allogeneic Islet Engraftment in Nonhuman Primates. Diabetes 59: 2558–2568.
- 13. Sordi V, Melzi R, Mercalli A, Formicola R, Doglioni C, et al. (2010) Mesenchymal cells appearing in pancreatic tissue culture are bone marrow-derived stem cells with the capacity to improve transplanted islet function. Stem Cells 28: 140–151.
- 14. Kerby A, Jones E, Jones P, King A (2012) Co-transplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. Cytotherapy: In press.
- 15. Rackham CL, Dhadda PK, Chagastelles PC, Simpson SJS, Dattani AA, Bowe JE, Jones PM, King AFJ (2012) Preculturing islets with Mesenchymal Stem Cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice. Cytotherapy: In press.
- 16. King A, Lock J, Xu G, Bonner-Weir S, Weir G (2005) Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48: 2074–2079.
- 17. Menger MD, Pattenier J, Wolf B, Jager S, Feifel G, et al. (1992) Cryopreservation of islets of Langerhans does not affect angiogenesis and revascularization after free transplantation. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 24: 89–96.
- 18. Morini S, Brown ML, Cicalese L, Elias G, Carotti S, et al. (2007) Revascularization and remodelling of pancreatic islets grafted under the kidney capsule. Journal of anatomy 210: 565–577.
- 19. Swarm RL (1963) Transplantation of a murine chondrosarcoma in mice of different inbred strains. J Natl Cancer 31: 953–975.
- 20. Hughes CS, Postovit LM, Lajoie GA (2010) Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 10: 1886–1890.
- 21. Pinkse GGM, Bouwman WP, Jiawan-Lalai R, Terpstra OT, Bruijn JA, et al. (2006) Integrin Signaling via RGD Peptides and Anti-β1 Antibodies Confers Resistance to Apoptosis in Islets of Langerhans. Diabetes 55: 312–317.
- 22. van Deijnen JH, Hulstaert CE, Wolters GH, van Schilfgaarde R (1992) Significance of the peri-insular extracellular matrix for islet isolation from the pancreas of rat, dog, pig, and man. Cell Tissue Res 267: 139–146.
- 23. Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13: 555–562.
- 24. Thomas FT, Contreras JL, Bilbao G, Ricordi C, Curiel D, et al. (1999) Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation. Surgery 126: 299–304.
- 25. Jalili RB, Moeen Rezakhanlou A, Hosseini-Tabatabaei A, Ao Z, Warnock GL, et al. (2011) Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal. J Cell Physiol 226: 1813–1819.
- 26. Kaido T, Yebra M, Cirulli V, Rhodes C, Diaferia G, et al. (2006) Impact of defined matrix interactions on insulin production by cultured human beta-cells: effect on insulin content, secretion, and gene transcription. Diabetes 55: 2723–2729.
- 27. Nagata N, Gu Y, Hori H, Balamurugan AN, Touma M, et al. (2001) Evaluation of insulin secretion of isolated rat islets cultured in extracellular matrix. Cell Transplant 10: 447–451.
- 28. Perfetti R, Henderson TE, Wang Y, Montrose-Rafizadeh C, Egan JM (1996) Insulin release and insulin mRNA levels in rat islets of Langerhans cultured on extracellular matrix. Pancreas 13: 47–54.
- 29. Salvay DM, Rives CB, Zhang X, Chen F, Kaufman DB, et al. (2008) Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 85: 1456–1464.
- 30. Hammar E, Parnaud G, Bosco D, Perriraz N, Maedler K, et al. (2004) Extracellular matrix protects pancreatic beta-cells against apoptosis: role of short- and long-term signaling pathways. Diabetes 53: 2034–2041.
- 31. Zhao Y, Xu J, Wei J, Li J, Cai J, et al. (2010) Preservation of Islet Survival by Upregulating α3 Integrin Signaling: The Importance of 3-Dimensional Islet Culture in Basement Membrane Extract. Transpl Proc 42: 4638–4642.
- 32. Dionne KE, Colton CK, Yarmush ML (1993) Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 42: 12–21.
- 33. Emamaullee JA, Stanton L, Schur C, Shapiro AM (2007) Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 56: 1289–1298.
- 34. Miao G, Ostrowski RP, Mace J, Hough J, Hopper A, et al. (2006) Dynamic production of hypoxia-inducible factor-1alpha in early transplanted islets. American journal of transplantation: official journal of the Am J Transplant 6: 2636–2643.
- 35. Carlsson PO, Liss P, Andersson A, Jansson L (1998) Measurements of oxygen tension in native and transplanted rat pancreatic islets. Diabetes 47: 1027–1032.
- 36. O'Sullivan ES, Johnson AS, Omer A, Hollister-Lock J, Bonner-Weir S, et al. (2010) Rat islet cell aggregates are superior to islets for transplantation in microcapsules. Diabetologia 53: 937–945.
- 37. Lau J, Carlsson PO (2009) Low revascularization of human islets when experimentally transplanted into the liver. Transplantation 87: 322–325.
- 38. Mattsson G, Jansson L, Carlsson PO (2002) Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 51: 1362–1366.
- 39. Mattsson G, Jansson L, Nordin A, Carlsson PO (2003) Impaired revascularization of transplanted mouse pancreatic islets is chronic and glucose-independent. Transplantation 75: 736–739.
- 40. Olsson R, Carlsson PO (2005) Better vascular engraftment and function in pancreatic islets transplanted without prior culture. Diabetologia 48: 469–476.
- 41. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, et al. (2006) Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization, and function. Diabetes 55: 2974–2985.
- 42. Johansson M, Olerud J, Jansson L, Carlsson PO (2009) Prolactin treatment improves engraftment and function of transplanted pancreatic islets. Endocrinology 150: 1646–1653.
- 43. Lai Y, Schneider D, Kidszun A, Hauck-Schmalenberger I, Breier G, et al. (2005) Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. Transplantation 79: 1530–1536.
- 44. Kampf C, Mattsson G, ran, Carlsson P-O (2006) Size-Dependent Revascularization of Transplanted Pancreatic Islets. Cell Transplant 15: 205–209.
- 45. Bosco D, Orci L, Meda P (1989) Homologous but not heterologous contact increases the insulin secretion of individual pancreatic B-cells. Exp Cell Res 184: 72–80.
- 46. Hauge-Evans AC, King AJ, Carmignac D, Richardson CC, Robinson IC, et al. (2009) Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58: 403–411.
- 47. Carvell MJ, Marsh PJ, Persaud SJ, Jones PM (2007) E-cadherin interactions regulate beta-cell proliferation in islet-like structures. Cell Physiol Biochem 20: 617–626.
- 48. Christoffersson G, Henriksnas J, Johansson L, Rolny C, Ahlstrom H, et al. (2010) Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes 59: 2569–2578.
- 49. Lund T, Korsgren O, Aursnes IA, Scholz H, Foss A (2010) Sustained Reversal of Diabetes Following Islet Transplantation to Striated Musculature in the Rat. J Surg Res 160: 145–154.
- 50. Gibly R, Graham J, Luo X, Lowe W, Hering B, et al. (2011) Advancing islet transplantation: from engraftment to the immune response. Diabetologia 54: 2494–2505.